ORAL PRESENTATION





Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2

L Liao^{1*}, M Bonsignori¹, K Hwang¹, AM Moody¹, R Park¹, S Crawford¹, H Chen¹, TL Jeffries¹, M Cooper¹, X Lu¹, R De¹, N Karasavvas², S Rerks-Ngarm³, S Nitayaphan⁴, J Kaewkungwal⁵, S Tovanabutra², P Pitisuttithum⁶, J Tartaglia⁷, F Sinangil⁸, J Kim², NL Michael², GD Tomaras¹, Z Yang⁹, K Dai⁹, M Pancera⁹, GJ Nabel⁹, JR Mascola⁹, PD Kwong⁹, A Pinter¹⁰, S Zolla-Pazner¹¹, MS Alam¹, BF Haynes¹

From AIDS Vaccine 2012 Boston, MA, USA. 9-12 September 2012

Background

The RV144 HIV-1 vaccine trial showed protection from HIV-1 acquisition with vaccine efficacy of 31.2%. Study of the immune correlates demonstrated an inverse association of V1/V2 antibodies with infection risk. A key task for HIV-1 vaccine development is to improve the level of efficacy seen in the RV144 trial with subsequent vaccine designs.

Methods


E.A244 V1/V2 Env tags contains an N-terminal Ig leader sequence and C-terminal Avi- and His6-tags linked to the V1/V2 domain, was expressed in 293F cells and purified by nickel column. Binding of Tier 1 neutralizing mAb CH58 from RV144 vaccinees, V2 conformational mAb 697D and broadly neutralizing antibodies (bnAb) CH01 and PG9/PG16 to 33 HIV-1 gp140/gp120s and 12 HIV-1 V1/V2 scaffold Envs was tested by ELISA and surface plasmon resonance.

Results

Among 45 HIV-1/SIV Envs tested, E.A244 V1/V2 tags and E.A244 gp120 Δ 11 Env were the only Env antigens recognized by all three types of mAbs: CH58, 697D, and bnAbs CH01, and PG9/PG16. E.A244 V1/V2 tag bound

¹Duke University Medical Center, Durham, NC, USA

Full list of author information is available at the end of the article



Conclusion

Recombinant E.A244 V1/V2 Env tags Env expresses linear as well as conformational determinants recognized by V1/V2 mAbs and some of their UAs. This V1/V2 construct is a candidate immunogen to target RUAs and intermediate ancestors of V1/V2 antibodies to drive their induction.

Author details

¹Duke University Medical Center, Durham, NC, USA. ²U.S. MHRP, Walter Reed Army Institute of Research, Silver Spring, MD, USA. ³Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand. ⁴Department of Retrovirology, US Army Medical Component, AFRIMS, Bangkok, Thailand. ⁵BIOPHICS, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. ⁶Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. ⁷Department of Research and Development, Sanofi Pasteur, Swiftwater, PA, USA. ⁸Global Solutions for Infectious Diseases, South San



© 2012 Liao et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Francisco, CA, USA. ⁹Vaccine Research Center/NIH, Bethesda, MD, USA. ¹⁰Public Health Research Institute Center, New Jersey Medical School, Newark, NJ, USA. ¹¹Veterans Affairs New York Harbor Healthcare System, Manhattan Campus, New York, NY, USA.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-O31

Cite this article as: Liao *et al.*: Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2. *Retrovirology* 2012 **9**(Suppl 2): O31.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

BioMed Central

Submit your manuscript at www.biomedcentral.com/submit